New Clinical Results from APOLLO Phase 3 Study of Patisiran at ICNMD

New Clinical Results from APOLLO Phase 3 Study of Patisiran at ICNMD

We presented new results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, at the International Congress on Neuromuscular Diseases (ICNMD), held July 6-10, 2018 in Vienna, Austria.

Obici et al. – “APOLLO Phase 3 Study: Impact of Baseline Neuropathy Severity on Response to Patisiran”

Coelho et al. – “Transthyretin Reduction with Patisiran in the APOLLO Phase 3 Study”

Mauermann et al. – “Impact of Patisiran on Autonomic Neuropathy in Hereditary Transthyretin-Mediated Amyloidosis Patients”

Goel et al. – “Population Pharmacokinetics (PK) of Patisiran in Healthy Volunteers and hATTR Patients”

Zhang et al. – “Pharmacokinetics of Patisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis”





Diese Website ist nur für Einwohner in Deutschland bestimmt.